Europe targets more joined-up health technology assessments

18 September 2023

european_union_commission_brussels_large

Significant changes to the way European health technology assessments (HTA) take place is underway, with a transitional period set to be in force for several years.

Agreed in 2022, the new Regulation on Health Technology Assessment is designed to usher in a new framework for cooperation between medicine regulators and HTA bodies in the region.

Due to come into effect in 2025, the rules will see the European Medicines Agency and national HTA bodies working together on joint clinical assessments, scientific consultations, and the identification of new health technologies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK